ClinicalTrials.gg
RecruitingNCT07221669STELLAR-1Updated Oct 23, 2026

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

A Phase 3 interventional study of Salanersen in Muscular Atrophy, Spinal, sponsored by Biogen. Recruiting at 14 sites in 7 countries. Open to participants aged 0 Days to 42 Days. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 23, 2026First sites in India and Chile3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
0 Days to 42 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Muscular Atrophy, Spinal by Biogen — 5 open to participants now, 10 under way, 4 of them phase 3. Muscular Atrophy, Spinal · Biogen.

Planned enrollment
16th of 21
30 · median 47
Started
2026
with 2 others
Phase 3
9 of 27
3 open now
Registered
25th of 27
by date

Among the 27 studies in Muscular Atrophy, Spinal by Biogen, this one is the 16th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 in phase 3, and was the 25th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 72 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

5 of the 27 studies in Muscular Atrophy, Spinal by Biogen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 57 Muscular Atrophy, Spinal studies recruiting now, 28 (49%) set no upper age limit and 26 (46%) stop at 75 or younger; 45 take children under 18; 11 take healthy volunteers.

This study: 0 Days to 42 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Atrophy, Spinal by Biogen, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen.

Specifically, researchers will learn more about how salanersen works in babies who have been diagnosed with SMA through genetic testing but have not yet started showing signs or symptoms. Most people with SMA have changes in a gene called survival motor neuron 1, also known as SMN1. These changes lower the amount of SMN protein in their bodies. Without enough of this protein, motor neurons and muscles cannot work properly. A similar gene called SMN2 can help replace some of the lost SMN protein in the body. Salanersen works by helping the SMN2 gene to make more SMN protein.

In this study, participants will have either 2 SMN2 copies or 3 SMN2 copies. The higher the copy number, the less severe the participant's SMA is.

The main goal of this study is to see if starting salanersen before signs or symptoms appear can prevent signs or symptoms of SMA or make them less severe. Researchers will use different tests to learn if motor symptoms are changing, including the World Health Organization (WHO) motor milestones.

The main questions researchers want to answer in this study are:

  • How many participants with 2 copies of the SMN2 gene can sit without support at 12 months?
  • How many participants with 3 copies of the SMN2 gene can walk alone at 18 months?

Researchers will also learn more about:

  • The effects on participants' motor symptoms and how many new movement milestones participants achieve.
  • How many participants stay free of SMA symptoms
  • How much salanersen gets into the fluid surrounding the brain and spinal cord.
  • How much salanersen gets into the blood.
  • How many participants have adverse events or serious adverse events. Adverse events are health problems that may or may not be caused by the study drug.

This study will be done as follows:

  • First, participants will be screened to check if they can join the study. The screening period will be up to 28 days.
  • This is an "open label" study. This is a study in which the participants, study doctor, and site staff know which study drug participants are receiving. In this study, all participants will receive salanersen through an intrathecal injection, or one that is given into the fluid surrounding the brain and spinal cord.
  • There will be 2 parts in this study. During Part 1, participants will receive 2 doses of salanersen, about 12 months apart from each other. Part 1 will last up to 25 months.
  • During Part 2, participants will continue to receive salanersen. They will receive up to 3 doses, 12 months apart from each other. Part 2 will last up to 36 months.
  • During Part 1, participants will have up to 11 clinic visits and up to 3 phone calls. During Part 2, participants will have up to 7 clinic visits and up to 12 phone calls.
Read the detailed description

For Part 1 of the study, the primary objective is to evaluate the clinical efficacy of salanersen in participants with genetically diagnosed SMA, and the secondary objective is to evaluate safety and tolerability, pharmacokinetics (PK), and effect on biomarkers after treatment with salanersen in participants with genetically diagnosed SMA.

For Part 2 of the study, the primary objective is to evaluate the long-term clinical efficacy of salanersen in participants with genetically diagnosed SMA, and the secondary objective is to evaluate the long-term safety and tolerability, PK, and effect on biomarkers after treatment with salanersen in participants with genetically diagnosed SMA.

03

Conditions studied

  • Muscular Atrophy, Spinal
04

Who can participate

Ages eligible
0 Days to 42 Days
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

-≤42 days of age at first dose of salanersen.

  • Genetic documentation of 5q SMA homozygous gene deletion or mutation or compound heterozygous mutation.
  • Two or three copies of the survival motor neuron 2 (SMN2) gene.
  • Ulnar compound muscle action potential (CMAP) amplitude ≥2 millivolt (mV) at Screening and Day 1 predose.
  • Body weight ≥3rd percentile for age based on World Health Organization (WHO) Child Growth Standards at the time of .

Key Exclusion Criteria:

  • Any clinical signs or symptoms at Screening or Day 1 predose that are, in the opinion of the Investigator, strongly suggestive of SMA.
  • Areflexia on neurologic examination at biceps, knee, or ankle at Screening or Day 1 Predose.
  • Hypoxemia (oxygen saturation \<96% awake or asleep without any supplemental oxygen or respiratory support, or for altitudes >1000 meters (m), oxygen saturation of \<92% awake or asleep without any supplemental oxygen or respiratory support).
  • Diagnosis of neonatal respiratory distress syndrome necessitating surfactant replacement therapy or invasive ventilatory support.
  • Any reason, anatomical or otherwise (including hematology/coagulation laboratory results), that presents increased risk of complication from the LP procedures or safety assessments.
  • Any prior treatment with an approved SMA disease-modifying therapy (e.g., nusinersen, onasemnogene abeparvovec-xioi [OA], and/or risdiplam), a myostatin inhibitor therapy, or an drug given for the treatment of SMA.

Note: Other protocol-defined inclusion/exclusion criteria will apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Salanersen

    In Part 1 of the study, participants will receive two doses of salanersen, 80 milligrams (mg) by intrathecal (IT) lumbar puncture (LP), approximately 12 months apart. Participants who complete Part 1 of the study will receive three doses of salanersen, 80 mg by IT LP, approximately 12 months apart, in Part 2 of the study.

    Drug: Salanersen

Interventions

  • Administered intrathecally

    Also known as: BIIB115

06

What researchers measure

Primary outcomes

  1. Part 1: Percentage of Participants with 2 Survival Motor Neuron 2 (SMN2) Copies Sitting Without Support (for at Least 10 Seconds)

    Time frame: At Month 12

  2. Part 1: Percentage of Participants with 3 SMN2 Copies Walking Alone (for at Least 5 Steps)

    Time frame: At Month 18

  3. Part 2: Percentage of Participants Attaining and Maintaining World Health Organization (WHO) Motor Milestones

    The WHO motor milestones will include six key developmental milestones: sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone, and walking alone.

    Time frame: Up to Day 1825

Secondary outcomes

  1. Part 1: Percentage of Participants Attaining World Health Organization (WHO) Motor Milestones

    The WHO motor milestones will include six key developmental milestones: sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone, and walking alone.

    Time frame: Up to Day 730

  2. Parts 1 and 2: Percentage of Participants Attaining Hammersmith Infant Neurological Examination Section 2 (HINE-2) Motor Milestones

    Section 2 of the HINE is used to assess motor milestones and includes 8 motor milestone categories: voluntary grasp (0 to 3), ability to kick in supine position (0 to 4), head control (0 to 2), rolling (0 to 3), sitting (0 to 4), crawling (0 to 4), standing (0 to 3), and walking (0 to 3). Total HINE-2 score is the sum of points from each item and can range from 0 to 26, with higher scores depicting a better level of ability.

    Time frame: Up to Day 1825

  3. Parts 1 and 2: Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale

    The CHOP INTEND test is designed to evaluate the motor skills of participants with significant motor weakness. It includes 16 items (capturing neck, trunk, and proximal and distal limb strength) structured to move from easiest to hardest with the grading including gravity eliminated (lower scores) to antigravity movements (higher scores). All item scores range from 0-4. The total score ranges from 0-64, with higher scores depicting better motor function.

    Time frame: Up to Day 1825

  4. Parts 1 and 2: Change From Baseline in Compound Muscle Action Potential (CMAP) Amplitudes

    CMAP is a well validated method for tracking disease progression in neuromuscular disorders such as SMA and amyotrophic lateral sclerosis and has been proposed as a potential biomarker of a therapeutic effect in SMA. CMAPs will be performed for the following nerve-muscle pairs: ulnar-abductor digiti minimi and peroneal-tibialis anterior.

    Time frame: Up to Day 1825

  5. Part 1: Percentage of Participants who Remain Free of Clinically Manifested Spinal Muscular Atrophy (SMA)

    Time frame: Up to Day 730

  6. Part 2: Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score

    The HFMSE is a tool used to assess motor function in individuals with SMA. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities.

    Time frame: Up to Day 1825

  7. Part 2: Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE)

    The HFMSE is a tool used to assess motor function in individuals with SMA. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities.

    Time frame: Up to Day 1825

  8. Part 2: Revised Upper Limb Module (RULM) Total Score

    The RULM is developed to assess upper limb functional abilities of participants with SMA. This test consists of a total of 20 upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function.

    Time frame: Up to Day 1825

  9. Part 2: Change From Baseline in Revised Upper Limb Module (RULM)

    The RULM is developed to assess upper limb functional abilities of participants with SMA. This test consists of a total of 20 upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function.

    Time frame: Up to Day 1825

  10. Part 2: Percentage of Participants who Develop Spinal Muscular Atrophy (SMA) Subtypes (Type 1, 2,3a and 3b) As Assessed by the Investigator

    Time frame: Up to Day 1825

  11. Parts 1 and 2: Time to Death (Overall Survival)

    Time frame: Up to Day 1825

  12. Parts 1 and 2: Time to Death or Permanent Ventilation

    Permanent ventilation is defined as tracheostomy or ≥16 hours ventilation/day continuously for \>21 days in the absence of an acute reversible event.

    Time frame: Up to Day 1825

  13. Parts 1 and 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Day 1825

  14. Parts 1 and 2: Concentration of Salanersen in Cerebrospinal Fluid (CSF)

    Time frame: Up to Day 1460

  15. Parts 1 and 2: Concentration of Salanersen in Serum

    Time frame: Up to Day 1825

  16. Parts 1 and 2: Change From Baseline in Plasma Levels of Neurofilament Light Chain (NfL)

    Time frame: Up to Day 1825

07

Study locations

14 of 14 sites recruiting
  • Ann and Robert H Lurie Childrens Hospital of Chicago
    Chicago, Illinois 60611, United States
    Recruiting
    • · Contact312-227-4637
    • Nancy Kuntz · Principal investigator
  • Neurology Rare Disease Center
    Flower Mound, Texas 75028, United States
    Recruiting
    • · Contact972-999-1011
    • Diana Castro · Principal investigator
  • Childrens Hospital of the Kings Daughter Norfolk
    Norfolk, Virginia 23507, United States
    Recruiting
  • Sydney Children's Hospital_Randwick
    Randwick, New South Wales 2031, Australia
    Recruiting
  • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
    Porto Alegre, Rio Grande do Sul 90560-030, Brazil
    Recruiting
    • · Contact55505359
    • Jonas Alex Morales Saute · Principal investigator
  • Hospital da Crianca de Brasilia
    Distrito Federal, 70684-831, Brazil
    Recruiting
    • · Contact55 800 002 2345
    • Janiana Monteiro · Principal investigator
  • PSEG Centro de Pesquisa Clinica
    Sai Paula, 4038002, Brazil
    Recruiting
    • · Contact55115572-4555
    • Paulo Victor Sgobbi de Souza · Principal investigator
  • Instituto Da Criança HC FMUSP
    São Paulo, 05403-900, Brazil
    Recruiting
    • · Contact55 11 2661-8500
    • Edmar Zanoteli · Principal investigator
  • Clinica MEDS La Dehesa_Lo Barnechea
    Lo Barnechea, 7691236, Chile
    Recruiting
    • · Contact+5 (698) 234-7983
    • Claudia Castiglioni · Principal investigator
  • The Third Affiliated Hospital of Zhengzhou University - North Campus
    Zhengzhou, Henan 450052, China
    Recruiting
  • Guangzhou Woman and Children's Medical Center_Guangzhou
    Guangzhou, 5106236, China
    Recruiting
  • Childrens Hospital of Fudan University_Shanghai
    Shanghai, 201122, China
    Recruiting
  • Royal Institute of Child Neurosciences
    Ahmedabad, Gujarat 380054, India
    Recruiting
    • · Contact+91-990996055
    • Siddharth Shah · Principal investigator
  • Japan Institute for Health Security National Center for Global Health and Medicine
    Tokyo, 162-8655, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2028, 31 months after the start.

Of 18 phase 3 interventional studies under Muscular Atrophy, Spinal, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2025
First posted
Oct 28, 2025
StartActual
Apr 28, 2026
Primary completionEst.
Nov 28, 2028
CompletionEst.
May 29, 2032
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first sites in India and Chile
Show 3 added (1 Brazil, 1 India, 1 Chile)
  • Instituto Da Criança HC FMUSP · São Paulo, Brazil
  • Royal Institute of Child Neurosciences · Ahmedabad, India
  • Clinica MEDS La Dehesa_Lo Barnechea · Lo Barnechea, Chile
across 3 updates, Oct 16, 2026 – Oct 23, 2026
Show all 3 updates
  1. Oct 23, 2026
    1 site added — first site in Chile
    Show site
    • Clinica MEDS La Dehesa_Lo Barnechea · Lo Barnechea, Chile
  2. Oct 21, 2026
    1 site added — first site in India
    Show site
    • Royal Institute of Child Neurosciences · Ahmedabad, India
  3. Oct 16, 2026
    1 site added
    Show site
    • Instituto Da Criança HC FMUSP · São Paulo, Brazil
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07221669
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 28, 2025
Start date
Apr 28, 2026
Primary completion
Nov 28, 2028 (estimated)
Completion
May 29, 2032 (estimated)
Last update
Oct 23, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salanersen

Start the discussion